Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Stalevo® in Subjects With Early Wearing-off Identified Using a Screening Tool WOQ-9; an Open, Non-randomised, Multinational, Multicentre 6-week Direct Switch Study in Levodopa-treated Parkinson's Disease Patients

NCT00462007 is registered in ClinicalTrials.gov with Orion Corporation, Orion Pharma as lead sponsor.

NCT NCT00462007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00462007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Stalevo® in Subjects With Early Wearing-off Identified Using a Screening Tool WOQ-9; an Open, Non-randomised, Multinational, Multicentre 6-week Direct Switch Study in Levodopa-treated Parkinson's Disease Patients
Lead sponsor
Orion Corporation, Orion Pharma
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2006
Completion date
December 31, 2007
Enrollment
115 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease